Emergent BioSolutions
NEWS
It was a busy week for clinical trial news. Here’s a look.
Gaithersburg, Md.-based Emergent BioSolutions offered an update on its Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19.
It was a moderately busy week for clinical trial news. Here’s a look.
Gaithersburg, Maryland-based Emergent BioSolutions inked another manufacturing agreement to support the development of a vaccine against COVID-19, the disease caused by the novel coronavirus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.
Emergent BioSolutions, a contract development and manufacturing organization, announced it had signed a public-private partnership under Operation Warp Speed worth about $628 million.
JOBS
IN THE PRESS